Showing results (131-140 of 189) with videos related to
Sort By:
Pageof 19
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.Journal of the American Academy of Dermatology|October 1, 1993
An evaluation of oral ulcers in patients with AIDS and AIDS-related complexG S Liang, G L Daikos, U Serfling, et al.Italian Journal of Pediatrics|May 23, 2019
Vernal Keratoconjunctivitis: an update focused on clinical grading systemA M Zicari, G Capata, M Nebbioso, et al.Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|June 1, 2007
Clinical utilization of near-infrared spectroscopy devices for burn depth assessmentK M Cross, L Leonardi, J R Payette, et al.Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.The British Journal of Dermatology|June 20, 2018
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switchesA Blauvelt, J-P Lacour, J F Fowler, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.Journal of the American Academy of Dermatology|May 19, 2015
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, et al.Journal of Drugs in Dermatology : JDD|August 16, 2021
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)Kim A Papp, Sascha Gerdes, Craig L Leonardi, et al.Pageof 19